Use of perioperative hydroxyethyl starch 6% and albumin 5% in elective joint arthroplasty and association with adverse outcomes: A Retrospective population based analysis

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Opperer, Mathias ^a,b   Poeran, Jashvant ^c,d   Rasul, Rehana ^d   Mazumdar, Madhu ^d   Memtsoudis, Stavros G ^a,b,e  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c Institute for Healthcare Delivery Science Department of Population Health Science and Policy   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HETASTARCH; ALBUMINOID; HETASTARCH DERIVATIVE; PLASMA SUBSTITUTE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; FLUID RESUSCITATION; HEART DISEASE; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; UNITED STATES; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; HIP REPLACEMENT; KNEE REPLACEMENT; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PROCEDURES; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; AGED; ALBUMINS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ELECTIVE SURGICAL PROCEDURES; FEMALE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PLASMA SUBSTITUTES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84926355941     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1567     Document Type: Article

References (41)

1. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013;2:CD000567. doi:10.1002/14651858.CD000567.pub6.
2. Bunn F, Trivedi D. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2012;7:CD001319. doi:10.1002/14651858.M CD001319.pub5.
3. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013;346:f839.
4. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013;309:678-88.
5. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012;367:1901-11.
6. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012;367:124-34.
7. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
8. US Food and Drug Administration. Hydroxyethyl starch solutions: FDA safety communication-boxed warning on increased mortality and severe renal injury and risk of bleeding. 2013. www.fda.gov/safety/ medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ ucm358349.htm.
9. European Medicines Agency. PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients. 2013. www.ema.europa.eu/ docs/en-GB/document-library/Press-release/2013/10/ WC500151964.pdf.
10. Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2013;7:CD007594. doi:10.1002/14651858.CD007594.pub3.
11. Bellomo R, Bion J, Finfer S, Myburgh J, Perner A, Reinhart K. Open letter to the executive director of the European Medicines Agency concerning the licensing of hydroxyethyl starch solutions for fluid resuscitation. Br J Anaesth 2014;112:595-600.
12. Coriat P, Guidet B, de Hert S, Kochs E, Kozek S, Van Aken H. Counter statement to open letter to the executive director of the European Medicines Agency concerning the licensing of hydroxyethyl starch solutions for fluid resuscitation. Br J Anaesth 2014;113:194-5.
13. Irwin MG, Gan TJ. Volume therapy with hydroxyethyl starches: are we throwing the anesthesia baby out with the intensive care unit bathwater? Anesth Analg 2014;119:737-9.
14. Skhirtladze K, Base EM, Lassnigg A, Kaider A, Linke S, Dworschak M, et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth 2014;112:255-64.
15. Roberts I, Blackhall K, Alderson P, Bunn F, Schierhout G. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2011;:CD001208. doi:10.1002/14651858.CD001208.pub4.
16. Premier. Premier Perspective Database. https://www.premierinc.com/ transforming-healthcare/healthcare-performance-improvement/ premier-research-services/.
17. Broderick JS, Henley MB. An introduction to orthopaedic coding and billing. J Orthop Trauma 2014;28(suppl 9):S12-4. doi:10.1097/ BOT.0000000000000178.
18. McDonald JS, McDonald RJ, Fan J, Kallmes DF, Lanzino G, Cloft HJ. Comparative effectiveness of ruptured cerebral aneurysm therapies: propensity score analysis of clipping versus coiling. AJNR Am J Neuroradiol 2014;35:164-9.
19. Rothberg MB, Pekow PS, Priya A, Zilberberg MD, Belforti R, Skiest D, et al. Using highly detailed administrative data to predict pneumonia mortality. PLoS One 2014;9:e87382.
20. Memtsoudis SG, Danninger T, Rasul R, Poeran J, Gerner P, Stundner O, et al. Inpatient falls after total knee arthroplasty: the role of anesthesia type and peripheral nerve blocks. Anesthesiology 2014;120:551-63.
21. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
23. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
24. Moineddin R, Matheson FI, Glazier RH. A simulation study of sample size for multilevel logistic regression models. BMC Med Res Methodol 2007;7:34.
25. Patel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 2013;39:811-22.
26. Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ 2014;349:g4561.
27. Van Der Linden P, James M, Mythen M, Weiskopf RB. Safety of modern starches used during surgery. Anesth Analg 2013;116:35-48.
28. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declère AD, et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013;310:1809-17.
29. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56.
30. Kancir ASP, Pleckaitiene L, Hansen TB, Ekeløf NP, Pedersen EB. Lack of nephrotoxicity by 6% hydroxyethyl starch 130/0.4 during hip arthroplasty: a randomized controlled trial. Anesthesiology 2014;121:948-58.
31. Kashy BK, Podolyak A, Makarova N, Dalton JE, Sessler DI, Kurz A. Effect of hydroxyethyl starch on postoperative kidney function in patients having noncardiac surgery. Anesthesiology 2014;121:730-9.
32. Hand WR, Whiteley JR, Epperson TI, Tam L, Crego H, Wolf B, et al. Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: a single-center retrospective review. Anesth Analg 2015;120:619-26.
33. Tinti F, Umbro I, Meçule A, Rossi M, Merli M, Nofroni I, et al. RIFLE criteria and hepatic function in the assessment of acute renal failure in liver transplantation. Transplant Proc 2010;42:1233-6.
34. Donnelly AJ. Albumin/hetastarch drug utilization review in an operating room pharmacy. Drug Intell Clin Pharm 1987;21:286-9.
35. Miletin MS, Stewart TE, Norton PG. Influences on physicians' choices of intravenous colloids. Intensive Care Med 2002;28:917-24.
36. Donaldson AJ, Thomson HE, Harper NJ, Kenny NW. Bone cement implantation syndrome. Br J Anaesth 2009;102:12-22.
37. Memtsoudis SG, Salvati EA, Go G, Ma Y, Sharrock NE. Perioperative pulmonary circulatory changes during bilateral total hip arthroplasty under regional anesthesia. Reg Anesth Pain Med 2010;35:417-21.
38. Chappell D, Jacob M. Hydroxyethyl starch-the importance of being earnest. Scand J Trauma Resusc Emerg Med 2013;21:61.
39. Martin C, Jacob M, Vicaut E, Guidet B, Van Aken H, Kurz A. Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. Anesthesiology 2013;118:387-94.
40. Dieterich H-J. Recent developments in European colloid solutions. J Trauma 2003;54:S26-30. doi:10.1097/01.TA.0000028408.13858.7A.
41. Danielson E. White paper: health research data for the real world: the MarketScan databases. Truven Health Analytics, 2014. http:// truvenhealth.com/Portals/0/Users/031/31/31/PH-13434 0314-MarketScan-WP-web.pdf.